What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter ...

Total Q3 2024 revenue: $151.7 million, down 1% YoY Instruments revenue fell 46%, while consumables revenue grew 10% The next correction is closer than you think. Find out how Tom Gentile plans to ...

After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics ...

Eight years ago, 10x Genomics launched the first commercially available single-cell RNA sequencing (scRNA-seq) product for the company’s flagship instrument, the 10x Chromium. (This occurred one year ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to ...

Computational assessment identifies probe binding errors in a widely used commercial platform for spatial transcriptomics.

Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable “virtual cell” models and other ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of the next generation of its high-performance Flex assay, featuring automation-compatible ...

“Illumina’s…presentations and product descriptions revealed a workflow that infringed on the ‘607, ‘138, ‘505, and ‘487 patents, 10x Genomics and Prognosys Biosciences argued.” On October 21, 10x ...